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Abstract
Background: The effectiveness of antiepileptic prophylaxis in patients with newly diagnosed 
high‑grade glioma is debated. Craniotomy, surgical manipulation and bleeding are believed 
to favor the onset of seizures and, therefore, perioperative antiepileptic drugs (AEDs) are 
generally used. Nevertheless, evidence to initiate preoperative AED prophylaxis are weak. 
Aim: Aim of this paper was to evaluate the need for AED prophylaxis in surgically‑treated 
malignant glioma patients without history of seizures. Materials and Methods: We 
conducted a retrospective, two‑center cohort study to assess the effectiveness of 
preoperative AED prophylaxis. Patients were divided in two groups: one with AED 
preoperative administration and the other without. Because of its non‑hepatic metabolism, 
levetiracetam (LEV) was chosen. Logistic regression models were used to investigate the 
odds ratio for each group. The explanatory variables included the treatment received, 
sex, age, and site of lesion. The outcome measure of successful LEV prophylaxis was 
seizure vs. no seizure post‑operatively, at three and six months after surgery. Results: Our 
results showed that LEV prophylaxis was not a significant predictor of seizure occurrence, 
although the regression coefficient indicated a slight reduction in seizure risk following LEV 
administration. Patient’s age was a significant predictor of seizure occurrence. Younger 
patients had a higher risk of seizure in the six months post‑surgery. Conclusions: We 
conclude that AEDs prophylaxis does not provide a substantial benefit to surgically treated 
high‑grade glioma patients and should not be administered routinely. Further investigations 
are required to detect subgroups of patients at higher risk of developing seizures in order 
to selectively administer AED.
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Introduction
Approximately 40% of high‑grade glioma patients 
present with seizures at onset.[1] Location of the glioma 
plays a role in epileptogenesis, and temporal and 
parietal lobes are more often associated with seizures 
than other areas of the brain. Patient age and previous 
cancer treatment also contribute to epileptogenesis.[2] If 
initiation of antiepileptic treatment is justified after a 
first and single seizure in patients with brain tumors, it 
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to brain tumor patients who have never had a seizure. 
Moreover, the majority of high‑grade glioma patients 
are treated surgically with a resection or biopsy, and the 
appearance of post‑operative seizures, both early and 
delayed is a predictable event. Surgical manipulation and 
bleeding usually generate inflammation and edema that 
are believed to favor the onset of seizures.[3,4] Furthermore, 
all glioblastoma (GBM) patients and a large percentage 
of grade III glioma patients are eventually treated with 
anticancer agents and steroids and, thus, the risk of 
potential drug interactions influences the choice of AED.
Existing brain damage from previous surgery or 
radiotherapy increases the risk of developing side effects 
from AEDs. A consensus statement from the Quality 
Standards Subcommittee of the American Academy of 
Neurology[2] recommends not to use AEDs routinely 
as prophylaxis in patients with brain tumors and to 
withdraw these drugs in the first week after surgery if 
patients have not had a seizure. The few analyses that 
have been conducted on AED prophylaxis in patients 
undergoing craniotomy,[3‑8] were confounded by the fact 
that different kinds of brain tumors (gliomas, metastasis, 
and meningiomas) were evaluated together, multiple 
AEDs were employed, and patients with preoperative 
seizures were included in the study. In clinical practice, 
many physicians continue to administer AEDs pre‑ and 
post‑operatively with the aim of avoiding seizures.
In the current study, we evaluated the need for AED 
prophylaxis in surgically‑treated high‑grade glioma 
patients with no history of seizures. With a follow‑up 
of at least six months, we also observed the difference 
in the appearance of delayed post‑operative seizures 
and long‑term adverse effects between AED‑treated 
patients and a control group. Because of its demonstrated 
efficacy, tolerability and non‑hepatic metabolism, we 




The retrospective, multicenter cohort study was 
conducted by the Division of Neurosurgery of the 
Hospitals of Turin and the Division of Neurosurgery of 
the Civil Hospital of Alessandria. The study period was 
January 2009 through December 2010.
In total, 143 patients harboring high‑grade gliomas 
were consecutively operated on in the Neurosurgical 
Divisions of Turin and Alessandria. Consistent 
with routine clinical practice, patients in the Turin 
neurosurgical department were treated with preoperative 
AED prophylaxis, but Alessandria patients were not. 
Patients who met the inclusion criteria for the study 
were divided into two cohorts. In Group A (Turin 
Hospital; LEV prophylaxis), patients received LEV as a 
prophylactic AED preoperatively, following the schedule 
described below. In Group B (Alessandria Hospital; 
control), only patients who did not receive prophylaxis 
were included.
Patients’ demographic data, tumor location, preoperative 
Karnofsky Performance Scale (KPS) score, post‑operative 
complications and histology were analyzed and 
differences in frequency according to patient group 
were calculated.
Inclusion criteria
Patients with newly‑diagnosed, untreated, supratentorial 
high‑grade gliomas without seizures were included 
in the study. Patients had no history of seizures or 
suspected anamnesis. Only patients with complete or 
subtotal resection of their tumor were selected. Complete 
resection was defined when the contrast‑enhanced 
tumor was no more visible on post‑contrast MR or CT 
performed the day after surgery.
Exclusion criteria
Patients with multicentric lesions or gliomas involving 
the midline, basal ganglia, cerebellum or brain stem were 
excluded from the study. Also, patients who experienced 
seizures as a symptom of disease or received treatment 
or prophylaxis with AED were excluded, as were those 
with a KPS score of less than 60.
Levetiracetam schedule
LEV was administered three to five days before surgery. 
The daily administration was 1 g (500 mg twice a day). 
In all cases, blood samples were drawn before surgery in 
order to evaluate the LEV plasma level. We performed 
surgery after achieving LEV serum levels above 15 ug/ml. 
We underline that the routine sample of the plasma level 
of LEV is actually our practice although it is not required 
for this kind of AED. The post‑operative LEV plasma 
concentration was also assessed. LEV was administrated 
after surgery according to the same schedule (500 mg 
twice a day) in the absence of seizures. The treatment 
was continued up to six months after surgery. If seizures 
occurred post‑operatively, the LEV dose was increased to 
2 g/day (1000 mg twice a day) or another AED was used.
Neuropathology
The histopathological criteria were established according 
to the World Health Organization 2007 diagnostic 
consensus criteria.[9]
Post‑operative evaluation and follow‑up
The post‑operative protocol was the same for all the 
patients and consisted of radiotherapy and concomitant 

















































































































Garbossa, et al.: Antiepileptic prophylaxis in high‑grade glioma surgery
29Neurology India | Mar-Apr 2013 | Vol 61 | Issue 2
assessed post‑operatively, then within 30 days after 
surgery and then checked at three and six months. 
The immediate post‑operative control is made by the 
surgeon, while the late post‑operative control (within 
one month from the operation) is conducted by the 
neurooncologist. Then, the neurooncologist follow‑up 
the patients at fixed intervals and collect the neurological 
status, as well as all the physical and neurological 
changes on standardized charts.
Statistical analysis
The outcome measure of successful LEV prophylaxis 
was seizure vs. no seizure at three and six months 
after surgery. Logistic regression models were used 
to investigate the odds ratio for groups A and B. The 
explanatory variables included the treatment received, 
sex, age, and site of lesion. Significant (P < 0.05) variables 
in the multiple regression analysis were found by the 
backward elimination method. Results are presented as 
odds ratios and 95% CIs.
Results
A total of 91 patients were included in the study (52 males 
and 39 females). Forty‑three patients were included in 
Group A and 48 patients in Group B. The Table 1 summarize 
the characteristics of the whole series of 143 patients based 
on the selection’s criteria. The participants’ ages ranged 
from 27 to 76 years; the mean age of the global sample 
was 61.8 years (SD = 12.03); the mean age of Group A 
was 59.47 years (SD = 12.0) and the mean age of Group B 
was 63.9 years (SD = 11.8). None of the patients enrolled 
in the analysis showed drug or psychotropic drug abuse 
and none suffered from other major neurologic diseases.
The most frequent symptoms at diagnosis were 
behavioural changes followed by hemiparesis and 
language or praxis disturbances. Headache, related to 
intracranial hypertension, was present in approximately 
25% of patients. Preoperative KPS score was over 80 in 
the majority of patients in both groups. Table 2 shows 
inter‑group differences in distributions of age, sex, 
preoperative KPS score, post‑operative complications, 
and histology.
Surgery was performed in all cases by means of 
craniotomy and resection of the contrast‑enhanced 
mass. Post‑operatively, urgent craniotomy was 
performed because of tumor cavity infarction in three 
patients (3.2%). All of these patients had a residual tumor 
left following surgery (deep position or tumor strictly 
adherent to vessels) and all three patients completely 
recovered after reoperation.
All patients harbored high‑grade gliomas, including 58 
GBM and 33 anaplastic astrocytomas (AA). Post‑operative 
LEV levels ranged between 15 and 40 ug/ml. Side effects 
were rare, with only one case of vertigo reported.
Group A
Early post‑operative period and thirty days after surgery
A 54‑year‑old male harboring a temporal GBM 
experienced seizures. A right temporal lobectomy 
was performed. The LEV dosage was increased to 
2000 mg/day with complete control of seizures.
Three‑month follow‑up
Five patients experienced seizures (2 temporal GBM, 
2 frontal GBM, and 1 parietal AA). First, the dose of 
Table 1: Summary of the whole series of 143 patients operated 
on for intracranial gliomas in both centers during the study 
period
Inclusion and exclusion criteria Enrolled (%) Excluded (%)
No seizures at diagnosis 91 (63.6)
Seizures at diagnosis 28 (19.5)




Already on AED prophylaxis 12 (8.3)*
Total number of patients (143) 91 (63.6) 52 (36.6)
KPS - Karnofsky performance scale, AED - Antiepileptic drugs patients 
are subdivided in those who matched the inclusion criteria and those who 
were excluded. (*) The patients in these two group have to be considered 
as subcategories as these subjects could also belong to the first two group 
(i.e., patients with multicentric glioma and KPS<60)
Table 2: Demographic details and characteristics
Features of patients and gliomas Group A (N=43) Group B (N=48) P value
Mean age (SD) 59.47 (12.0) 63.9 (11.8) t 
(89)
=1.77; P=0.08
Sex (N): Male/female (ratio) 28/15 (1.87) 24/24 (1.0) χ2=2.12; P=0.15 
Preoperative KPS score>80 40 (43.9%) 44 (48.3%) U=1029.5; P=0.98
Postoperative complications 1 (1%) 2 (2.1%)
N° of GBM 27 (29.6%) 31 (34%) χ2=0.032; P=0.86 
N° of grade III anaplastic 16 (17.5%) 17 (18.6%)
Site of tumor
Frontal 20 (21.9%) 21 (23%) χ2=1.064; P=0.79
Occipital 3 (3.2%) 2 (2.1%)
Parietal 5 (5.4%) 4 (4.3%)
Temporal 15 (16.4%) 21 (23%)
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LEV was increased to 2000 mg/day. Complete seizure 
control was achieved in three cases. In two patients, we 
observed a poor response and treatment was changed 
to a multi‑drug approach (carbamazepine 1200 mg/day 
and sodium valproate 1000 mg/day) with subsequent 
stabilization of the seizures.
Six‑month follow‑up
Two patients experienced seizures. Partial control was 
achieved by increasing LEV to 2000 mg/day. After dose 
adjustment, one patient showed severe ataxia. LEV 
was stopped and changed over to sodium valproate 
1200 mg/day with partial seizure control and ataxia 
improvement.
Group B
Early post‑operative period and thirty days after surgery
No seizures were observed in the perioperative period.
Three‑month follow‑up
Three patients developed focal seizures. No response 
to LEV 2000 mg/day was observed among these 
patients, and treatment was switched to oxcarbazepine 
900 mg/day with complete seizure control.
Six‑month follow‑up
Six patients experienced seizures. Complete control 
was obtained with LEV 2000 mg/day in three cases. 
However, good control was not achieved in three 
patients and treatment was switched to oxcarbazepine 
900 mg/day with partial control of seizures.
Data analysis
The rate of seizure occurrence within one month after 
surgery was globally very low (2.3% in Group A, while 
no patients in Group B had seizures). Since the rate of 
seizures in the perioperative period was extremely low, 
we could not include these data in the statistical analysis. 
At three months, the cumulative rates of seizure were 
13.9% in Group A and 6.2% in Group B. At six months, 
the cumulative rates of seizure were 18.5% in Group A 
and 18.75% in Group B. All the patients that developed 
seizures in the follow‑up period were different from 
those who presented seizures in the perioperative 
period. Table 3 reports the frequency of seizures at the 
post‑operative and follow‑up period.
We tested the effect of LEV prophylaxis on the 
occurrence of seizures within six months post‑surgery 
by fitting the data to a logistic regression model, which 
determines the effect of an independent variable to 
predict membership of one or other of the two dependent 
variable categories (occurrence vs. no occurrence). 
Treatment was the independent variable, i.e. the effect of 
the treatment was included as predictor of the occurrence 
of seizure; age and gender were entered as covariates, 
which are variables that may be related to the event 
under investigation (i.e. the occurrence of seizure). LEV 
prophylaxis was not a significant predictor of seizure 
occurrence (b = ‑0.140, P = 0.818, OR = 0.869), although 
the regression coefficient indicated a slight reduction 
in seizure risk following LEV administration. Patients 
age was a significant predictor of seizure occurrence 
(b = ‑0.049, P = 0.042, OR = 0.952). Younger patients had 
a higher risk of seizure in the six months post‑surgery; 
for each 10‑year increase in age, a patient›s odds of 
seizure decreased by 39% (OR = 0.613). The regression 
coefficient suggested a lower risk of seizures in males, 
but the effect of gender was not significant (b = ‑0.842, 
P = 0.159, OR = 0.431). Two‑way interactions between 
treatment, age, and gender were further tested and found 
to be non‑significant. The data are displayed in Table 4.
Discussion
The frequency of seizures in patients harboring 
supratentorial brain tumors is as high as 40%[2,10] 
and surgery itself is believed to add a relevant risk 
of perioperative seizures.[11] Several clinicians and 
neurosurgeons use AEDs as prophylaxis in order to 
prevent seizures,[12] despite potential adverse effects and 
drug interactions. Moreover, high‑grade glioma patients 
are frequently exposed to neurosurgery, radiotherapy and 
chemotherapy and, therefore, they present particular risks 
to the initiation and maintenance of additional therapy.
First‑generation AEDs such as phenytoin, carbamazepine, 
valproic acid and phenobarbital have been used to 
treat seizures in patients with glioma. These agents 
are known to cause a higher incidence of side effects, 
Table 3: Occurrence of post‑operative seizures at early 
post‑operative period (until 30 days after surgery), three 









Early post‑operative 1 (1.1) 0
Three months 5 (5.4) 3 (3.2)
Six months 2 (2.1) 6 (6.5)
Total 8 (8.7) 9 (9.8)
LEV - Levetiracetam
Table 4: Logistic regression analysis of risk of seizure in 
surgically treated high‑grade gliomas patients
Predictor b SE Wald χ2 P OR
Intercept 1.782 1.534 1.35 0.245 ‑
LEV prophylaxis 
(0=no; 1=yes)
−0.140 0.606 0.053 0.818 0.869
Age (years) −0.049 0.024 4.121 0.042 0.952
Gender (0=F; 1=M) −0.842 0.599 1.981 0.159 0.431
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especially phenytoin, whose most feared side effect is 
Stevens‑Johnson syndrome.[13‑15] Moreover, phenytoin, 
like many other first generation AEDs, undergoes 
oxidative metabolism through the hepatic cytochrome 
P450 (CYP) system; phenytoin is an enzyme‑inducing 
AED and can potentially increase the clearance of 
chemotherapeutic agents metabolized through the 
CYP system including antineoplastic drugs used for 
glioma therapy.[16,17] Interactions between antiepileptic 
drugs and antineoplastic agents may lead to insufficient 
control of the tumor or epilepsy or to toxic effects 
of one or both of the agents. Drug interactions are 
usually pharmacokinetic‑based and affect drug uptake, 
metabolism in the liver, or elimination of the drug.
Enzyme‑inducing AEDs decrease the effectiveness of 
corticosteroids and several chemotherapeutic agents. 
Oberndorfer and colleagues[18] conducted a retrospective 
study of patients with GBM who were given adjuvant 
chemotherapy (most received lomustine), and found 
that overall survival of patients who received an 
enzyme‑inducing antiepileptic drug (most received 
carbamazepine) was significantly shorter than for those who 
received a non‑enzyme‑inducing antiepileptic drug (most 
received valproic acid; 10.8 vs. 13.9 months, respectively). 
More recently, different authors demonstrated how LEV 
and valproic acid can increase the activity of and the 
response to chemotherapy.[19,20] On the other hand, many 
chemotherapeutic agents induce coenzymes of the CYP 
pathway and change the plasma concentration of AEDs.[16]
New antiepileptic drugs such as gabapentin, LEV, and 
pregabalin do not interact with other agents, as they do 
not influence the CYP or other metabolic pathways. To 
date, few side effects associated with LEV have been 
reported, including dizziness, disturbed mood, fatigue 
and somnolence, in several series[18,21‑24] of patients 
with brain tumors who received antineoplastic agents 
simultaneously. Therefore, LEV has been increasingly 
used as an AED for brain tumor patients over the 
past decade, particularly in patients undergoing early 
post‑operative chemotherapy.[18,25]
The precise mechanisms by which LEV exerts its 
antiepileptic effect is unknown, but it is thought to 
stimulate synaptic vesicle protein 2A (SV2A), which 
inhibits neurotransmitter release. In animal models, 
LEV did not inhibit single seizures induced by 
maximal stimulation with electrical current or different 
chemoconvulsants and showed only minimal activity 
in submaximal stimulation and in threshold tests.[26] 
Protection was observed, however, against secondarily 
generalized activity from focal seizures induced by 
pilocarpine and kainic acid, two chemoconvulsants 
that induce seizures that mimic some features of human 
complex partial seizures with secondary generalization, 
and in the kindling model in rats, another model 
mimicking partial seizures.
The issue of AED prophylaxis in brain tumor patients 
has been extensively discussed in the last two decades 
and AED prophylaxis has been proposed for some 
indications.[27] The major evidences were revealed 
when authors started performing meta‑analyses 
of several works on this topic. In 2001, Temkin[28] 
analyzed six prospective, controlled trials that involved 
patients undergoing neurosurgery for different 
diagnoses (tumors, trauma) and found that AED 
prophylaxis (predominantly phenytoin) reduced 
seizures in the early post‑operative period. This 
work had the great limitation of comparing patients 
belonging to populations with very different risks of 
seizure (trauma and tumor patients) and the author 
admitted the need for studies on homogeneous categories 
of patients. A large meta‑analysis performed by Glantz 
et al.,[2] evaluated 12 studies involving brain tumor 
patients (either randomized controlled or cohort studies), 
but no demonstration of the efficacy of prophylaxis was 
disclosed. The authors failed to solve the matter because 
the study models were not completely suitable. As a 
matter of fact, they were retrospective studies or did 
not have placebo‑controlled patients. Moreover, the 
pooling of patients harboring different kind of tumors 
with different risks of seizure (meningiomas, metastasis, 
gliomas) made those results less robust. In 2002, De 
Santis.[29] published a prospective work that evaluated 
the usefulness of prophylaxis in the specific category of 
surgically‑treated supratentorial tumor patients. They 
found that phenytoin was not able to prevent seizures, 
either as monotherapy or in cases where an AED was 
already administered. This study had the important 
limitation of including subjects already suffering from 
seizures preoperatively and patients previously treated 
with AED. In order to focus on patients without seizures 
at onset and assemble a larger population of patients, 
Sirven[30] performed a meta‑analysis of five studies 
that dealt with only seizure‑free patients (a total of 403 
subjects), but only three included patients undergoing 
craniotomies. All these studies had the advantage of 
being prospective and placebo‑controlled, but patients 
with different kinds of tumors were included and, in 
some studies, multiple AEDs were employed. Moreover, 
all the AEDs were last generation drugs. Four of these 
studies could not demonstrate the efficacy of AED 
prophylaxis and surgery did not influence the risk of 
seizure onset.
The most evident limitation of the current study is its 
retrospective structure, but performing a prospective 
trial on this topic would have been troublesome in 
relation to the number of patients to enrol and the 
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although the use of cohorts from different hospitals 
could have introduced some bias, it is worth noting 
that these two Institutions share the same surgical 
and post‑operative protocol, that is the indications 
for surgery are similar, as well as the methods of 
following‑up patients. In this work, we investigated 
the occurrence of post‑operative seizure in a large 
sample of patients, revealing no significant effect of 
LEV prophylaxis on seizure occurrence. Our results 
provide additional insight into the cost/benefit analysis 
of LEV prophylaxis, although further studies on larger 
samples are needed to accurately detect a small effect.
Our findings indicate that the prophylactic administration 
of LEV does not provide a substantial benefit to 
surgically‑treated high‑grade glioma patients. This 
may be due to the low dose of LEV employed for 
prophylactic treatment, compared to that used in 
acute treatment, owing to the need to limit side effects 
for a long‑term administration. In fact, a review 
of the data in the literature on the possible role of 
prophylactic antiepileptic treatment with traditional 
agents (phenytoin, phenobarbital, carbamazepine) 
for early post‑operative seizures shows that the main 
reason for therapeutic failure is subtherapeutic serum 
concentrations of the drugs. In some studies, serum 
concentration monitoring was not conducted, making it 
impossible to establish whether the drug was ineffective 
or not.[25,28] In the current study, post‑operative LEV 
plasma concentrations were within the therapeutic range 
in all the patients.
Conclusions
Antiepileptic prophylaxis in patients with intracranial 
tumors is still a matter of debate. In this specific category 
of patients with high‑grade gliomas undergoing 
craniotomy, AED prophylaxis should not be administered 
routinely. Further investigations detecting subgroups 
of patients at higher risk of developing seizures 
post‑operatively (i.e. younger patients) are welcome in 
order to selectively administer AED prophylaxis.
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